Corrigendum: Case report: Challenges in the diagnosis of a case of Mal de Meleda and a therapeutic attempt of ixekizumab and Adalimumab

Yuwei Dai; Xiaodong Zheng; Qi Zhang; Xia Hu; Peiguang Wang; Sen Yang

doi:10.3389/fmed.2022.1106530

Corrigendum: Case report: Challenges in the diagnosis of a case of Mal de Meleda and a therapeutic attempt of ixekizumab and Adalimumab

Front Med (Lausanne). 2022 Dec 12:9:1106530. doi: 10.3389/fmed.2022.1106530. eCollection 2022.

Authors

Yuwei Dai^{1

2

3

4

5}, Xiaodong Zheng^{1

2

3

4}, Qi Zhang^{1

2

3

4

5}, Xia Hu^{1

2

3

4

5}, Peiguang Wang^{1

2

3

4}, Sen Yang^{1

2

3

4

5}

Affiliations

¹ Department of Dermatology, The First Affiliated Hospital, Anhui Medical University, Hefei, China.
² Institute of Dermatology, Anhui Medical University, Hefei, China.
³ Key Laboratory of Dermatology, Anhui Medical University, Ministry of Education, Hefei, China.
⁴ Provincial Laboratory of Inflammatory and Immune Mediated Diseases, Hefei, China.
⁵ Ferry Outpatient Department, The Ferry Skin Research Institute, Hefei, China.

Abstract

[This corrects the article DOI: 10.3389/fmed.2022.821301.].

Keywords: Adalimumab; Exomiser; HPO terms; Ixekizumab; MDM; Mal de Meleda.

Publication types

Published Erratum